Old Web
English
Sign In
Acemap
>
authorDetail
>
Tom Macek
Tom Macek
Takeda Pharmaceutical Company
Schizophrenia
Psychology
Psychiatry
Working memory
Electroencephalography
3
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
1012. The Relationships of the Pharmacokinetics of TAK-063 to the Cognitive and Mood Effects of the Compound in a Multiple Dose, Phase 1 Study in Healthy Japanese Subjects and Subjects With Schizophrenia
2017
Biological Psychiatry
Tom Macek
Maggie McCue
Paul Goldsmith
Jinhui Xie
John Affinito
Keith Wesnes
Show All
Source
Cite
Save
Citations (0)
M20. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
2017
Schizophrenia Bulletin
Tom Macek
Maggie McCue
Francis Ogrinc
Elizabeth Hanson
Paul Goldsmith
John Affinito
Atul R. Mahableshwarkar
Show All
Source
Cite
Save
Citations (2)
Changes in EEG markers by TAK-063 in subjects with stable schizophrenia have different temporal relationships with changes in working memory
2017
European Neuropsychopharmacology
Tom Macek
Maggie McCue
Jinhui Xie
Keith Wesnes
P.H. Boeijinga
Show All
Source
Cite
Save
Citations (0)
1